To test this mechanism, control and IGF2BP2 overexpression or knockdown thyroid cancer cells were treated with 5 μg/mL RNA synthesis inhibitors actinomycin (ActD). The gene discussed is IGF2BP2; the disease is thyroid gland carcinoma.